{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:49:43Z","timestamp":1772754583557,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1016\/j.jaad.2004.05.013","type":"journal-article","created":{"date-parts":[[2004,9,24]],"date-time":"2004-09-24T23:13:32Z","timestamp":1096067612000},"page":"580-584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases"],"prefix":"10.1016","volume":"51","author":[{"given":"Melissa Amy","family":"Magliocco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice Bendix","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2004.05.013_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0889-857X(03)00047-4","article-title":"Current treatment of psoriatic arthritis","volume":"29","author":"Mease","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2004.05.013_bib2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2004.05.013_bib3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.05.013_bib4","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.05.013_bib5","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2004.05.013_bib6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2004.05.013_bib7","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.05.013_bib8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clindermatol.2003.08.015","article-title":"Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis","volume":"21","author":"Victor","year":"2003","journal-title":"Clin Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2004.05.013_bib9","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1186\/ar552","article-title":"Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases","volume":"4","author":"Kalden","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.jaad.2004.05.013_bib10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1378\/chest.124.5.2028","article-title":"Refractory sarcoidosis responding to infliximab","volume":"124","author":"Roberts","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jaad.2004.05.013_bib11","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2004.05.013_bib12","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1345\/aph.1C039","article-title":"Infliximab treatment of rheumatoid arthritis and Crohn's disease","volume":"37","author":"Nahar","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2004.05.013_bib13","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2004.05.013_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1568010023344535","article-title":"TNF-alpha as therapeutic target: new drugs, more applications","volume":"1","author":"Reimold","year":"2002","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"10.1016\/j.jaad.2004.05.013_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14712598.3.1.141","article-title":"Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases","volume":"3","author":"Braun","year":"2003","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaad.2004.05.013_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/bega.2002.0345","article-title":"Strategies for targeting tumour necrosis factor in IBD","volume":"17","author":"Sandborn","year":"2003","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jaad.2004.05.013_bib17","first-page":"635","article-title":"Mechanisms for modulating TNF alpha in immune and inflammatory disease","volume":"4","author":"Baugh","year":"2001","journal-title":"Curr Opin Drug Discovery Dev"},{"key":"10.1016\/j.jaad.2004.05.013_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/ar592","article-title":"Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches","volume":"4","author":"Braun","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.jaad.2004.05.013_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrd1175","article-title":"Anti-TNF-alpha therapies: the next generation","volume":"2","author":"Palladino","year":"2003","journal-title":"Nature Rev Drug Discovery"},{"key":"10.1016\/j.jaad.2004.05.013_bib20","series-title":"Viral hepatitis and liver disease","first-page":"267","article-title":"A population-based serologic study of hepatitis C virus infection in the United States","author":"McQuillan","year":"1997"},{"key":"10.1016\/j.jaad.2004.05.013_bib21","first-page":"297","article-title":"Apoptosis and pathogenesis of viral hepatitis C\u2014an update","volume":"14","author":"Nasir","year":"2000","journal-title":"In Vivo"},{"key":"10.1016\/j.jaad.2004.05.013_bib22","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1023\/A:1018804426724","article-title":"Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection","volume":"42","author":"Nelson","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaad.2004.05.013_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1084\/jem.179.3.841","article-title":"Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis","volume":"179","author":"Gonzalez-Amaro","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2004.05.013_bib24","unstructured":"Zein NN. A phase II randomized, double blind, placebo controlled study of tumor necrosis factor antagonist (etanercept, Enbrel) as an adjuvant to interferon and ribavirin in naive patients with chronic hepatitis C [abstract]. 53rd Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2002."},{"issue":"Suppl","key":"10.1016\/j.jaad.2004.05.013_bib25","first-page":"38","article-title":"Safety of TNF-a antagonists in patients with rheumatoid arthritis and chronic hepatitis C","volume":"61","author":"Peterson","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.05.013_bib26","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.05.013_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09546630310020470","article-title":"Etanercept therapy in patients with autoimmunity and hepatitis C","volume":"14","author":"Khanna","year":"2003","journal-title":"J Dermatol Treat"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962204013088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962204013088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:35:04Z","timestamp":1759268104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962204013088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0190962204013088"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2004.05.013","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2004.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}